Simulations Plus (SLP) Stock Price
Simulations Plus Price
Over the last 19 years Simulations Plus grew revenue by 14.7% annually, reaching 79.18 M USD. Earnings per share have grown at 15.0% per year over the last 18 years. For Simulations Plus, the net margin of -81.7% is down versus 21.1% a few years ago. At today's price the dividend yield works out to roughly 0.97%. The payout ratio is around 37% of earnings. The consensus 12-month price target for Simulations Plus is 18.50 USD, about 0.0% above where the stock trades today. Of 12 analysts, 0 rate the stock a buy — an overall Sell consensus.
Simulations Plus stock price
Simulations Plus business model & stock analysis
Frequently asked questions about Simulations Plus
Simulations Plus Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on simulation software and consulting services, the company provides cutting-edge solutions for drug discovery and development. Simulations Plus Inc's expertise in modeling and simulation technologies helps pharmaceutical companies optimize their drug formulation and dosage strategies. By leveraging their industry-leading software platforms, Simulations Plus Inc supports the efficient research and development of new therapies, enhancing the overall success and effectiveness of pharmaceutical companies.
The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.
The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.
Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.
Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.
Simulations Plus Inc is primarily present in the United States.
Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.
Analysts currently set an average price target of 18.50 USD for the Simulations Plus stock (median: 18.50 USD), implying +0.0 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Simulations Plus stock: 0 recommend buying, 7 holding and 5 selling. For 2026, analysts expect Simulations Plus to generate revenue of 81.95 M USD and earnings per share of 0.86 USD.
Converted at the current exchange rate, the Simulations Plus share trades at 16.51 EUR (18.50 USD).
The Simulations Plus share (SLP) is listed on 1 stock exchanges, including: NASDAQ (SLP).
Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.
The expected revenue of Simulations Plus is 81.95 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Simulations Plus is 17.49 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Simulations Plus is currently 21.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Simulations Plus stock.
The price-to-sales ratio (P/S) of Simulations Plus is currently 4.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Simulations Plus stock.
The Eulerpool Quality Score for Simulations Plus is 3/10.
The ISIN of Simulations Plus is US8292141053. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Simulations Plus is 924294. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Simulations Plus is SLP. The ticker symbol is used to trade Simulations Plus shares on the stock exchange.
Simulations Plus stock
Simulations Plus Peer Group
Simulations Plus Ticker
Simulations Plus FIGI
All fundamentals and in-depth analysis of Simulations Plus
Our stock analysis for Simulations Plus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Simulations Plus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.